<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670122</url>
  </required_header>
  <id_info>
    <org_study_id>FJD-TAN-14-01</org_study_id>
    <nct_id>NCT02670122</nct_id>
  </id_info>
  <brief_title>Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC</brief_title>
  <official_title>Prospective, Multicenter, Non Randomized, Single Arm Study to Evaluate Safety of Transarterial Chemoembolization (TACE) With Doxorubicin Eluting 100 µ Microspheres in Patients With Non Resectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, multicenter, single arm, prospective study to evaluate safety and&#xD;
      tolerability of selective and ultraselective drug eluting beads transcatheter intraarterial&#xD;
      chemoembolization (DEB-TACE) with up to 3 ml of well calibrated 100 µ microspheres and up to&#xD;
      150 mg of doxorubicin, for the treatment of non resectable hepatocellular carcinoma (HCC).&#xD;
&#xD;
      The hypothesis is that 100 µ beads penetrate deeper into the tumor than those eluting beads&#xD;
      with larger volumes without increasing the risk and complications of DEB-TACE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this observational, prospective study patients will undergo DEB-TACE and subsequent follow&#xD;
      up procedures according to standard clinical practice. The primary aim of the study is to&#xD;
      describe treatment safety and tolerability of 100 µ beads in DEB-TACE. As a secondary&#xD;
      end-point a description of efficacy parameters will be obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>30 days</time_frame>
    <description>Major and minor complications, procedure related mortality and post-embolisation syndrome after DEB-TACE of non-resectable HCC, using 100-µm doxorubicin-loaded microspheres</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>6 months, 1 year, 2 year</time_frame>
    <description>Devascularization pattern in the treated tumor, assessed with the modified RECIST (mRECIST), in the contrast enhanced liver CT or MR obtained during FU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">131</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with non resectable HCC</arm_group_label>
    <description>DEB-TACE with doxorubicin eluting 100 µ microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEB-TACE</intervention_name>
    <description>Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.</description>
    <arm_group_label>Patients with non resectable HCC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Target population includes:&#xD;
&#xD;
          -  Patients with stage B HCC carcinoma according to Barcelona Clinic Liver Cancer&#xD;
             classification (BCLC).&#xD;
&#xD;
          -  Patients with stage A HCC according to BCLC if they are not candidates or not willing&#xD;
             to go through surgery or radiofrecuency.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of HCC according to European Association for the Study of&#xD;
             the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD)&#xD;
             criteria and staged by BCLC criteria&#xD;
&#xD;
          2. Indication for receiving transarterial chemoembolization DEB-TACE with 100 µ&#xD;
             microspheres according to usual clinical practice.&#xD;
&#xD;
          3. Able and willing to participate and give their written informed consent.&#xD;
&#xD;
          4. Both genders and ≥ 18 years old.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) 0&#xD;
&#xD;
          6. Preserved hepatic function (Child-Pugh ≤ B7).&#xD;
&#xD;
          7. No evidence of tumoral invasion in portal vein or main biliary ducts.&#xD;
&#xD;
          8. Able to go through image diagnostic techniques such as CT or MRI.&#xD;
&#xD;
          9. Preserved cardiac and renal function.&#xD;
&#xD;
         10. No concomitant active infections that require antibiotic treatment.&#xD;
&#xD;
         11. Measurable disease according to mRECIST criteria.&#xD;
&#xD;
         12. Life expectancy over 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ECOG ≥ 1&#xD;
&#xD;
          2. Child-Pugh ≥B8.&#xD;
&#xD;
          3. Presence of ascitis or encephalopathy&#xD;
&#xD;
          4. Extrahepatic tumoral disease.&#xD;
&#xD;
          5. Tumoral vascular invasion&#xD;
&#xD;
          6. Serum bilirubin&gt;3 mg/dl.&#xD;
&#xD;
          7. Cr Clearance ≤ 60 ml/min&#xD;
&#xD;
          8. If any of the following is contraindicated:&#xD;
&#xD;
               1. Administration of doxorubicin&#xD;
&#xD;
               2. Iodated contrasts&#xD;
&#xD;
               3. CT or MRI procedures&#xD;
&#xD;
               4. Transarterial embolization procedures&#xD;
&#xD;
               5. White blood cells (WBC) &lt; 2000 /mm3&#xD;
&#xD;
               6. Neutrophil count &lt; 1500 /mm3&#xD;
&#xD;
               7. Ejection fraction &lt; 50 %&#xD;
&#xD;
               8. Platelet count &lt; 5 x 104/mm3, international normalized ratio (INR) &gt; 2,0)&#xD;
&#xD;
               9. Transaminases (AST and/or ALT) &gt; 5x upper limit of normal or &gt;250 u/l&#xD;
&#xD;
              10. Known hepatofugal portal vein flow&#xD;
&#xD;
              11. A-V intrahepatic macroscopic fistula&#xD;
&#xD;
          9. Pregnant or breast feeding women.&#xD;
&#xD;
         10. Tumor burden involving more than 50% of the liver.&#xD;
&#xD;
         11. Active bacterial or fungal infection.&#xD;
&#xD;
         12. Other concomitant tumors.&#xD;
&#xD;
         13. Any other condition that according to investigator criteria, contraindicates DEB-TACE.&#xD;
&#xD;
         14. Patients not willing to participate and/or give their written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Urbano, MD, PhD,EBIR</last_name>
    <role>Principal Investigator</role>
    <affiliation>HRyC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <results_first_submitted>February 10, 2020</results_first_submitted>
  <results_first_submitted_qc>March 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2021</results_first_posted>
  <last_update_submitted>March 27, 2021</last_update_submitted>
  <last_update_submitted_qc>March 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Jose Urbano Garcia</investigator_full_name>
    <investigator_title>MD, PhD, EBIR</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02670122/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02670122/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prospective inclusion from march 2015 to november 2016 in 10 University Hospitals</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients With Non Resectable HCC</title>
          <description>DEB-TACE with doxorubicin eluting 100 µ microspheres&#xD;
DEB-TACE: Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127">18 patients recieved liver transplantation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Non Resectable HCC</title>
          <description>DEB-TACE with doxorubicin eluting 100 µ microspheres&#xD;
DEB-TACE: Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.64" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Technical success rate</title>
          <description>Technical success is defined as the achievement of vascular stasis in the tumor feeding arteries or the administration of the full drug dose, with no technical complications during the DEB-TACE procedure.</description>
          <units>DEB-TACE procedures</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability</title>
        <description>Major and minor complications, procedure related mortality and post-embolisation syndrome after DEB-TACE of non-resectable HCC, using 100-µm doxorubicin-loaded microspheres</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Major Complications</title>
            <description>Common Terminology Criteria for Adverse Events 4.03 grade 3 or 4 adverse events</description>
          </group>
          <group group_id="O2">
            <title>Minor Complications</title>
            <description>Common Terminology Criteria for Adverse Events 4.03 grade 1 or 2 adverse events</description>
          </group>
          <group group_id="O3">
            <title>Procedure Related Mortality</title>
            <description>Patients that died due to the DEB-TACE procedure</description>
          </group>
          <group group_id="O4">
            <title>Severe PES</title>
            <description>Severe Post Embolisation Syndrome is when due to the pain and/or fever caused by the DEB TACE procedure requires intravenous analgesia and extend hospital admission.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Major and minor complications, procedure related mortality and post-embolisation syndrome after DEB-TACE of non-resectable HCC, using 100-µm doxorubicin-loaded microspheres</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Response</title>
        <description>Devascularization pattern in the treated tumor, assessed with the modified RECIST (mRECIST), in the contrast enhanced liver CT or MR obtained during FU.</description>
        <time_frame>6 months, 1 year, 2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6 m ORR</title>
            <description>Objective Response Rate as the sum of complete and partial response rate 6 months after the first DEB-TACE</description>
          </group>
          <group group_id="O2">
            <title>12 m ORR</title>
            <description>Objective Response Rate as the sum of complete and partial response rate 12 months after the first DEB-TACE</description>
          </group>
          <group group_id="O3">
            <title>24 m ORR</title>
            <description>Objective Response Rate as the sum of complete and partial response rate 24 months after the first DEB-TACE</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>Devascularization pattern in the treated tumor, assessed with the modified RECIST (mRECIST), in the contrast enhanced liver CT or MR obtained during FU.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS</title>
        <description>Overall survival</description>
        <time_frame>2 years</time_frame>
        <population>Patients that completed 2 year follow up. Patients losf for FU and the patients who recieved recieved liver transplantation are censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Survival</title>
            <description>OS is defined as the cumulative 24-month survival rate.</description>
          </group>
        </group_list>
        <measure>
          <title>OS</title>
          <description>Overall survival</description>
          <population>Patients that completed 2 year follow up. Patients losf for FU and the patients who recieved recieved liver transplantation are censored.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="13" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>CTCAE 4.03 criteria</desc>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events</title>
          <description>Mortality, minor and major adverse events after Tandem-100 DEB-TACE were assessed in accordance with CTCAE 4.03 criteria</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>HCC rupture and bleeding. Embolization 10h after TACE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>SIRS systemic inflammatory response syndrome, CKD chronic kidney disease. ICU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Abcess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cholecistitis, conservative management</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of a severe COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Severe PES</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Partial alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic segmentary bile duct/biliary tree dilatation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Biloma. Conservative treatment.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Asymtomatic segmental hepatic artery dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>big groing hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Asymptomatic coagulative thrombosis of a segmental portal branch (LWH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Asymptomatic segmental hepatic artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Periumbilical bruise (non target falciform artery embolization)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lack of a comparative arm using larger or smaller DEBs or a cTACE group.&#xD;
Intratumor doxorubicin doses were calculated according to the mL of injected mirospheres</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jose Urbano Garcia, MD, PhD, EBIR, FCIRSE</name_or_title>
      <organization>Ramon y Cajal University Hospital. Vascular and Interventional Radiology Service</organization>
      <phone>+ 34 606 31 84 30</phone>
      <email>jurbano34@gmail.com ; jurbano@salud.madrid.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

